2010
Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer
Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. Journal Of Clinical Oncology 2010, 28: 1821-1828. PMID: 20231683, PMCID: PMC2860366, DOI: 10.1200/jco.2009.25.3286.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnthracyclinesAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsBridged-Ring CompoundsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantDisease ProgressionFemaleHumansMiddle AgedNeoadjuvant TherapyReceptors, EstrogenReceptors, ProgesteroneSurvival RateTaxoidsTreatment OutcomeYoung AdultConceptsHigh Ki-67 scoreNeoadjuvant chemotherapyKi-67 scoreStable diseaseBreast cancerEstrogen receptorMultivariate analysisDistant disease-free survivalER/PR negativityFirst-line surgical approachTumor progressionMost breast cancer patientsDisease-free survivalStandard neoadjuvant chemotherapyCancer clinical stageAmerican Joint CommitteeBreast cancer patientsAfrican American raceAdvanced tumor stagePredictors of responseHigh nuclear gradeHigh tumor gradeNegative estrogen receptorNovel molecular predictorsPR negativity
2007
HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer
Pusztai L, Andre F, Mazouni C, Liedtke C, Kau S, Frye D, Green M, Gonzalez-Angulo A, Symmans W, Hortobagyi G. HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer. Journal Of Clinical Oncology 2007, 25: 548-548. DOI: 10.1200/jco.2007.25.18_suppl.548.Peer-Reviewed Original ResearchPathologic complete responseHER2 overexpressionPCR rateBreast cancerER- cancersHER2 expressionHER2- diseaseRelapse-free survival rateER-negative statusWeekly paclitaxel regimenMicrotubule associated protein tauHigh nuclear gradePaclitaxel regimenPreoperative paclitaxelFAC chemotherapyPreoperative chemotherapyComplete responseHER2 tumorsHER2 statusDoxorubicin chemotherapyNuclear gradeRetrospective analysisPatientsTaxane sensitivitySurvival rateDifferential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer
Liedtke C, Mazouni C, Hess K, Tordai A, André F, Symmans W, Gonzalez-Angulo A, Green M, Hortobagyi G, Pusztai L. Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer. Journal Of Clinical Oncology 2007, 25: 10519-10519. DOI: 10.1200/jco.2007.25.18_suppl.10519.Peer-Reviewed Original ResearchTriple-negative statusHigh nuclear gradeTriple-negative breast cancerTriple-negative tumorsLong-term survivalBreast cancerNuclear gradeNeoadjuvant chemotherapyOverall survivalNegative tumorsIndependent unfavorable prognostic factorHER2/neu expressionMD Anderson Cancer CenterComplete pathological responseProgesterone receptor expressionInvasive breast cancerPositive nodal statusTriple-negative groupUnfavorable prognostic factorAnderson Cancer CenterBasal-like subtypeRetrospective comparative analysisNegative control groupNeoadjuvant trialsRemainder patients